Available for Partnership

Oncology
Indication
Modality
Research
H2L
Lead Opt
IND enabling
Clinical phase
Multiple Cancers
Small molecule
RAS
Pediatric Cancer
Cell therapy
NK activating cells
Small molecule
Chemogenomic
Breast Cancer
Small molecule
Estrogen receptor
Small molecule
Ran GTPase
Small molecule
mRNA translation inhibitors
Small molecule
VDR/HDAC dual therapeutic agents
Small molecule
ERK3 and ERK4 inhibitors
Ovarian Cancer
Small molecule
Ran GTPase
Oncolytic Virus
HER2
Cell therapy
CAR-T
Chemoresistance
Small molecule
mutated Keap1
Small molecule
Glucuronidases
RARE DISEASES
Indication
Modality
Research
H2L
Lead Opt
IND enabling
Clinical phase
ARSACS (Ataxia)
Small molecule
TBD
Immune Thrombocytopenic Purpura (ITP)
Small molecule
Neuraminidase
OTHER
Indication
Modality
Research
H2L
Lead Opt
IND enabling
Clinical phase
Neurology
Small molecule
Nur77/RXR

Partnered Projects

Oncology
Indication
Modality
Target/Strategy
Partner
Location
Solid Tumor
Small molecule
Kinase
France
Biotherapy
Tumor specific antigen
Medigene
Germany
Small molecule
Kinase
BMS
US
Hematological Tumors
Cell Therapy
I/O
ExCellThera
Québec, Canada
Small molecule
Mitochondrial target
BMS
US
Biotherapy
Tumour specific antigen
AbbVie
US
Small molecule
mRNA translation
Pharmascience
Québec, Canada
Small molecule
Chemogenomics
Amorchem, BMS
Québec, Canada / US
OTHER
Indication
Modality
Target/Strategy
Partner
Location
Metabolic Disorder
Small molecule
GPCR
Domain Therapeutics, ONO
France, Japan
Cardiovascular
Small molecule
GPCR
BMS
US
Biotherapy
GPCR
BMS
US
Inflammatory
Biotherapy
GPCR
BMS
US
Small molecule
GPCR
BMS
US
Small molecule
Surface receptor
MaRS Innovation (TIAP), Zealand Pharma
Ontario, CANADA, DANEMARK
DRUG DISCOVERY PLATFORM
Indication
Modality
Target/Strategy
Partner
Location
BRET biosensor
N/A
Domain Therapeutics
France
N/A
Platform DEL
BMS
US

© 2008-2022 IRICoR